SCHEMBL717892

SCHEMBL717892

CC(=O)NC1CCN(c2nc3c(Cl)cccc3cc2C(C)Nc2nc(C)nc(N)n2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.39
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
PIK3R2 O00459 1/20 0.38
SMO Q99835 1/20 0.37
KRAS P01116 1/20 0.37
SOS1 Q07889 1/20 0.37
CNR2 P34972 4/20 0.36
CNR1 P21554 3/20 0.36
TPH1 P17752 1/20 0.36
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35
EGFR P00533 2/20 0.35
PIK3CD O00329 4/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
HRH4 Q9H3N8 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717891 1.00 LRRK2 (0.39) LRRK2STK4STK3PIK3R2SMO
SCHEMBL715976 0.89 LRRK2 (0.44) LRRK2STK4STK3SMOKRAS
SCHEMBL715977 0.89 LRRK2 (0.44) LRRK2STK4STK3SMOKRAS
SCHEMBL713704 0.88 CNR1 (0.41) PIK3R2SMOCNR2CNR1PIK3CD
SCHEMBL713703 0.88 CNR1 (0.41) PIK3R2SMOCNR2CNR1PIK3CD
SCHEMBL714766 0.87 PIK3CD (0.43) KRASSOS1CNR2TPH1PIK3CD
SCHEMBL714765 0.87 PIK3CD (0.43) KRASSOS1CNR2TPH1PIK3CD
SCHEMBL714861 0.86 PIK3CD (0.42) PIK3R2CNR2CNR1PIK3CD
SCHEMBL714860 0.86 PIK3CD (0.42) PIK3R2CNR2CNR1PIK3CD
SCHEMBL715264 0.86 MAPT (0.42) PIK3R2SOS1CNR1PIK3CDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 LRRK2 617/4885STK4 106/4885STK3 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.